Margaret Kyle
Margaret Kyle

STRATEGY
Visiting Professor of Strategy

Print Overview

Margaret Kyle (MINES ParisTech and IDEI) studies innovation, productivity and competition.  She has a number of papers examining R&D productivity in the pharmaceutical industry, specifically the role of geographic and academic spillovers; the firm-specific and policy determinants of the diffusion of new products; generic competition; and the use of markets for technology.  Recent work examines the effect of trade and IP policies on the level, location and direction of R&D investment and competition. She also works on issues of innovation and access to therapies in developing countries. Her papers have been published in various journals of economics, strategy, and health policy, including the RAND Journal of Economics, Review of Economics and Statistics, Journal of Law and Economics, Strategic Management Journal, Health Services Research, and Health Affairs.

Margaret holds a PhD in economics from the Massachusetts Institute of Technology.  She previously held positions at Carnegie Mellon University, Duke University and London Business School.  She has also been a visiting scholar at the Center for the Study of Innovation and Productivity at the Federal Reserve Bank of San Francisco and at the University of Hong Kong.  She is a Research Associate at the Centre for Economic Policy Research.



Print Vita
Education
Ph.D., 2002, Economics, Massachusetts Institute of Technology, Massachusetts Institute of Technology
B.S. , 1995, Economics, Cornell University, Cornell University, Honors

Academic Positions
Visiting Professor, Northwestern University, 2014-present
Professor, MINES ParisTech, 2014-present
Visiting Professor, University of Hong Kong, 2013-2013
Professeur, Institut d'Administration des Enterprises, Universite de Toulouse 1 and Toulouse School of Economics, 2010-2014
Professeur associe, Universit e de Toulouse 1 and Toulouse School of Economics, 2009-2010
Assistant Professor, London Business School, 2006-2010
Assistant Professor, Fuqua School of Business, Duke University, 2004-2006
Assistant Professor, Tepper School of Business, Carnegie Mellon University, 2002-2004

Other Professional Experience
Research Assistant, Board of Governors of the Federal Reserve System, 1995-1997

Print Research
Research Interests
Industrial Organization, Productivity, Economics of Innovation, Health Policy, Business Strategy

Articles
Kyle, Margaret. 2004. Does Locale Affect R&D Activity? The Case of Pharmaceuticals. Federal Reserve Bank of San Francisco Economic Letter.
Kyle, Margaret and John M. de Figueiredo. 2005. Product Launch Decisions by Dominant and Fringe Firms. Best Paper Proceedings of the Academy of Management.
Kyle, Margaret, Mercedes Delgado and Anita McGahan. 2013. Intellectual Property Protection and the Geography of Trade. Journal of Industrial Economics. 61(3): 733-762.
Kyle, Margaret and Anita McGahan. 2012. Investments in Pharmaceuticals Before and After TRIPS. Review of Economics and Statistics. 94(4): 1157-1172.
Kyle, Margaret, Henry Grabowski, Richards Mortimer, Geina Long and Noam Kirson. 2011. Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act. Health Affairs. 30: 2157-2166.
Kyle, Margaret, Till Barnighausen, Joshua Salomon and Brenda Waning. 2011. Assessing the population health impact of market interventions to improve access to antiretroviral treatment. Health Policy and Planning.
Kyle, Margaret. 2011. Strategic Responses to Parallel Trade. B.E. Journal of Economic Analysis & Policy. 11(2): 2.
Kyle, Margaret, Brenda Waning, Ellen Diedrichsen, Lyne Soucy, Jenny Hochstadt, Till Barnighausen and Suerie Moon. 2010. Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. Globalization and Health. 6(9)
Kyle, Margaret and Kevin Schulman. 2008. Does Re-importation Reduce Price Differences for Prescription Drugs? Lessons from the European Union. Health Services Research. 43(4): 1308-1324.
Kyle, Margaret and David Ridley. 2007. Would Greater Price Transparency and Uniformity Benefit Poor Patients?. Health Affairs. 26(5): 1384-1391.
Kyle, Margaret and Henry Grabowski. 2007. Generic Competition and Market Exclusivity Periods in Pharmaceuticals. Managerial and Decision Economics. 28(4-5): 491-502.
Kyle, Margaret. 2007. Pharmaceutical Price Controls and Entry Strategies. Review of Economics and Statistics. 89(1): 88-99.
Kyle, Margaret. 2006. The Role of Firm Characteristics in Pharmaceutical Product Launches. RAND Journal of Economics. 37(3): 602-618.
Kyle, Margaret, Glenn Pransky, Ernst R. Berndt, Stan Finkelstein, Joan Mackell and Dan Tortorice. 2006. Objective and Self-ReportedWork Performance Measures: A Comparative Analysis. International Journal of Productivity & Performance Management. 55(5): 390-399.
Kyle, Margaret and John M. de Figueiredo. 2006. Surviving the Gales of Creative Destruction: The Determinants of Product Turnover. Strategic Management Journal. 27(3): 241-264.
Kyle, Margaret, Jeffrey M. Furman, Iain M Cockburn and Rebecca M. Henderson. 2005. Public & Private Spillovers, Location, and the Productivity of Pharmaceutical Research. Annales d'Economie et Statistique. 79/80: 165-188.
Kyle, Margaret, Ernst R. Berndt, Joan Mackell and Dan Tortorice. 2002. Measuring health impacts on work performance: Comparing subjective and objective reports. Value in Health. 5(6): 448-449.
Kyle, Margaret, Ernst R. Berndt and Davina Ling. 2002. Deregulating Direct-to-consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-counter Sales. Journal of Law and Economics. 44(3): 691-723.
Book Chapters
Kyle, Margaret, Allen Berger and Joseph M. Scalise. 2001. "Did U.S. Bank Supervisors Get Tougher During the Credit Crunch? Did it Matter to Bank Lending?." In Prudential Supervision: What Works and What Doesn't, edited by Frederic Mishkin, Chicago: University of Chicago Press.
Kyle, Margaret and Henry Grabowski. 2008. "Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity." In The Economics of Corporate Governance and Mergers, edited by Klaus Peter Gugler and B. Burcin Yurtoglu, Cheltenham, UK: Edward Elgar Publishing.
Kyle, Margaret and Cheri Grace. 2009. "Comparative advantages of push and pull incentives for technology development: lessons for neglected diseases." In Global Forum Update on Research for Health.
Kyle, Margaret. 2009. "Parallel Trade in Pharmaceuticals: Firm Responses and Competition Policy." In International Antitrust Law & Policy: Fordham Competition Law 2009, edited by Barry Hawk, New York: Juris Publishing.
Kyle, Margaret and Henry Grabowski. 2012. "Consolidation and Productivity in the Pharmaceutical Industry." In Handbook of the Economics of the BioPharmaceutical Industry, edited by P. Danzon and S. Nicholson, Oxford.
Kyle, Margaret and FionaScott Morton. 2012. "Markets for Pharmaceutical Products." In Handbook of Health Economics, edited by M.V. Pauly, T.G. McGuire, and P.P. Barros, 763-823. Elsevier.
Kyle, Margaret and Henry Grabowski. 2013. "Alliances, Mergers and Acquisitions." In Elsevier Encyclopedia of Health Economics, edited by Anthony J. Culyer, Elsevier.
Conference Proceedings
Kyle, Margaret, Ernst R. Berndt and Davina Ling. 2003. "The Long Shadow of Patent Expiration: Do Rx to OTC Switches Provide an Afterlife?." In NBER Conference Volume on Scanner Data and Price Indexes, 229-267. Chicago: University of Chicago Press.

 
Print Teaching
Full-Time / Part-Time MBA
Pharmaceutical Strategy (HEMA-931-B)
The pharmaceutical industry is a large, global and innovative sector. Advances in science and technology have required substantial changes to the organization and orientation of pharmaceutical firms. It has experienced substantial consolidation, entry by small, focused firms, and growth in specialized firms such as contract research organizations. The industry is also highly regulated, with many country-specific laws and policies. These features pose important challenges to the management of global firms. Each class meeting will include lecture material and a case discussion. The purpose of these sessions is to provide an overview of the institutional environment and "stylized facts" about pharmaceutical markets.